(Alliance News) - Solvonis Therapeutics PLC on Friday said it raised GBP1.0 million gross from subscriptions to new shares, and this will fund development of drugs treating addiction and other mental health disorders. Read More
(Alliance News) - Solvonis Therapeutics PLC on Monday said the US Patent & Trademark Office has allowed a core patent application covering compounds in its artificial-intelligence-enabled central-nervous-system discovery programme, granting protection in the US's drug market for at least 18 years. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Solvonis Therapeutics PLC on Tuesday announced the appointment of neuroscience professor David Nutt as its chief scientific officer, with immediate effect. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Solvonis Therapeutics PLC said on Wednesday that it will be focusing on funding its research projects, after reporting no sources of revenue for its latest year. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Solvonis Therapeutics PLC on Wednesday reported "positive progress" on its European patent application for the Awkn-Sdn-14 programme. Read More
(Alliance News) - Solvonis Therapeutics PLC on Monday said it entered into an arrangement agreement to buy Toronto-based Awakn Life Sciences Corp. Read More